INTRODUCTION
Axonal transport defects are thought to contribute to the pathogenesis of neurodegenerative disorders and restoring transport is suggested to be a therapeutic strategy. Post-translational modification of microtubules is a major regulator of axonal transport. One such modification, acetylation of a-tubulin, has been studied intensively in neurodegeneration. It promotes axonal transport by recruiting the molecular motor proteins kinesin-1 and cytoplasmic dynein to microtubules (1, 2) . Decreased acetylation of a-tubulin underlies the transport defects in Huntington's disease (HD) and Charcot -MarieTooth disease (CMT) (1, 3) . Moreover, neuroprotective effects of genetic or pharmacological inhibition of Hdac6 and Sirt2, the two major a-tubulin deacetylases, have been reported in models of HD, CMT and Parkinson's disease (PD) (1,3 -6) . However, these enzymes have several other functions in the cell. For instance, Sirt2 has recently been suggested to play a role in programmed necrosis (7) . In particular however, Hdac6 plays a major role in the degradation of misfolded proteins that play a causal role in the mechanism of neurodegeneration. It can bind ubiquitinated proteins and dynactin simultaneously (8) . It thus enhances transport of ubiquitinated proteins by the cytoplasmic dynein motor to the microtubule-organizing center where these are degraded through the autophagy machinery (9) . This ubiquitin-dependent function of Hdac6 is dependent upon the a-tubulin deacetylase activity of this enzyme (8, 9) . Thus, deacetylase inhibition may have deleterious effects as well. It is therefore necessary to evaluate the net effect of the inhibition of these multifunctional enzymes before accepting them as favorable therapeutic targets.
Amyotrophic lateral sclerosis (ALS) is a progressive, incurable and fatal condition characterized by the loss of upper and lower motor neurons. Its molecular pathogenesis is multifactorial and modified by non-neuronal cells (10, 11) . In animal models of ALS, axonal transport defects are present early in life, well before the onset of clinical deficits (12, 13) . The relevance of axonal transport dysfunction for human ALS is demonstrated by the occurrence of spheroids, axonal swellings packed with filamentous material, in familial and sporadic ALS (14, 15) . In order to elucidate whether deacetylase inhibitors may be a promising avenue for intervention in ALS, we investigated the effect of Hdac6 and Sirt2 deletion on the motor neuron degeneration in the superoxide dismutase 1, SOD1 G93A , mouse model of ALS.
RESULTS

Hdac6 or Sirt2 knockout does not affect neuromuscular function in mice
In this study, we have used Sirt2 knockout (KO) mice, obtained by mating conditional Sirt2 KO mice (16) with CMV-Cre mice, and Hdac6 KO mice (17) . We confirmed the absence of Hdac6 and Sirt2 protein from nervous tissues of Hdac6 KO and Sirt2 KO mice, respectively ( Fig. 1A and  B) . In wild-type mice, mainly the smaller 39 kDa isoform of Sirt2 was expressed as reported before (18) . Analysis of Sirt2 mRNA expression levels revealed a complete loss of Sirt2 in homozygous Sirt2 KO mice (Sirt2 2/2 ) and a 50% decrease in heterozygous Sirt2 KO mice (Sirt2 +/2 ) compared with control littermates (Sirt2 +/+ ) (Fig. 1C) . As a result of the location of the Hdac6 gene on the X-chromosome, there is variable protein expression in heterozygous females as a result of lionization, and male mice-who share only one X-chromosome-are either non-transgenic or full KO. Therefore, no heterozygous Hdac6 KO mice were used in this study.
We first excluded that the deletion of either Hdac6 or Sirt2 results in a neuromuscular phenotype on itself. Motor performance was evaluated using an accelerating rotarod and was not different between Hdac6 KO mice and control mice (Supplementary Material, Fig. S1A ) or between Sirt2 KO and control mice (Supplementary Material, Fig. S1B ). The compound muscle action potential (CMAP), an electrophysiological measure of neuromuscular innervation, of Hdac6 KO and Sirt2 KO mice was not different from control mice (Supplementary Material, Fig. S1C and D) . To exclude more subtle changes, we quantified the number of neurons in the ventral horn of lumbar spinal cord as well as the fraction of innervated neuromuscular junctions (NMJs) in the gastrocnemius muscle. No differences in these parameters were detected (Supplementary Material, Fig. S2 ).
Effect of deletion of Hdac6 on the course of motor neuron degeneration in SOD1 G93A mice
Hdac6 KO mice were crossbred with SOD1 G93A mice. As disease onset and survival of SOD1 G93A mice vary between litters and genders (19) (Fig. 2C ). To confirm the survival benefit observed, we studied the CMAP in age-matched (130 days of age), symptomatic littermates, and quantified the innervation of their NMJs as well as the remaining neurons in the ventral spinal cord. CMAP amplitudes in SOD1 G93A /Hdac6 Y/2 mice were significantly higher compared with control SOD1 G93A /Hdac6 Y/+ mice ( These results indicate that Hdac6 is a major a-tubulin deacetylase in the nervous system and that absence of Hdac6 does not induce neuromuscular abnormalities. Deletion of Hdac6 from the SOD1 G93A mouse significantly slowed the progression of motor neuron degeneration, suggesting that in this condition the beneficial effects of the absence of this enzyme (e.g. on axonal transport) outweigh its hazardous effects (e.g. on autophagy). Effect of deletion of Sirt2 on the course of motor neuron degeneration in SOD1 G93A mice
To study the effect of Sirt2 deletion, we crossed SOD1 G93A mice with Sirt2 KO mice. In contrast to what was observed for Hdac6, Sirt2 deletion did not affect disease onset or survival of SOD1 G93A mice (Fig. 4A and B) . In line with this lack of effect on behavioral disease parameters, we did not find any difference in CMAP amplitude or number of remaining neurons in the ventral spinal cord of symptomatic SOD1 G93A /Sirt2 +/+ mice and SOD1 G93A mice deficient for Sirt2 ( Fig. 4C and D) . Reduction of Sirt2 did not change SOD1 G93A expression (Fig. 3A and Supplementary Material, Fig. S3A ).
To further explore the discrepancy between the effects of Hdac6 KO versus Sirt2 KO, we studied the effect of Sirt2 deletion on the acetylation of a-tubulin in end-stage SOD1 G93A mice. In contrast to what we found in Hdac6-deficient mice, we did not find any difference in the level of acetylated a-tubulin upon deletion of Sirt2 (Fig. 3 and Supplementary  Material, Fig. S3 ). We confirmed this lack of effect at an earlier disease stage in age-matched (160 days of age) symptomatic littermates (Supplementary Material, Fig. S4 ). To exclude a confounding effect of the presence of SOD1 G93A and to elucidate whether Sirt2 actually regulates a-tubulin acetylation in the nervous system at all, we analyzed a-tubulin acetylation in spinal cord, brain and sciatic nerve of Sirt2 KO mice. Surprisingly, but consistent with the results obtained, no differences in a-tubulin acetylation were present (Supplementary Material, Fig. S5 ). To exclude that the absence of Sirt2 was compensated for by upregulation of Hdac6, we quantified Hdac6 expression in 80-day-old and 250-day-old Sirt2 KO mice, but found no alteration of Hdac6 mRNA in spinal cord and brain (Supplementary Material, Fig. S6 ).
These data suggest that although Sirt2 is clearly expressed in the nervous system (Fig. 1A) , its contribution to the regulation of a-tubulin acetylation in this tissue is minor. Deletion of Sirt2 does not induce neuromuscular abnormalities on itself and also fails to modify the disease course in the SOD1 G93A mouse.
DISCUSSION
Inhibitors of Hdac6 and Sirt2 have been suggested to be potential treatments for neurodegenerative diseases as they increase Protein accumulations can arise from deregulated transport, and in turn block the transport of other proteins, organelles and vesicles. Hence, improving axonal transport by inhibiting a-tubulin deacetylation is thought to be a strategy to treat these diseases. Genetic and pharmacological inhibitions of Hdac6 and Sirt2 have been studied in a variety of neurodegenerative disorders, such as HD, PD, Alzheimer's disease (AD), spinal and bulbar muscular atrophy (SBMA) and CMT (1, 3, (21) (22) (23) , but these studies have generated contradictory results. In models of AD and SBMA, Hdac6 activation rather than inhibition was beneficial, (22, 23) . In contrast, in a model of HD, Hdac6 inhibition rescued the impaired transport of the brain-derived neurotrophic factor (BDNF) in striatal neurons in vitro (1). However, in an in vivo mouse model of HD, genetic deletion of Hdac6 failed to modify disease progression or BDNF transport (24) . In a CMT mouse model, Hdac6 inhibition reversed the phenotype in vivo and rescued the axonal transport defects (3). In cellular and Drosophila models of PD and HD, inhibition of Sirt2 was reported to have neuroprotective effects (4 -6) . These variable results may be explained by the fact that these enzymes have several different functions and several different substrates in the cell. This is particularly true for Hdac6, which plays an important role in autophagy through its ubiquitin-binding ability (8, 9) . The involvement of this enzyme in both axonal transport and misfolded protein degradation argues for a dual role of this protein in neurodegeneration. Depending on the type of neurodegeneration and perhaps even the disease stage, the importance of enhanced autophagy may outweigh the importance of restored axonal transport.
Ever since axonal swellings-resulting from neurofilament accumulations-have been observed in familial and sporadic ALS (14, 15) , defects in axonal transport are intensively studied in ALS. In order to elucidate whether increasing axonal transport through a-tubulin deacetylase inhibitors may be a promising avenue for intervention in this disease, we investigated the effect of Hdac6 and Sirt2 deletion on the motor neuron degeneration in the SOD1 G93A mouse model of ALS. The absence of the Hdac6 protein did not result in a neuromuscular phenotype on behavioral and physiological levels. This is consistent with previous findings of Bobrowska et al., who tested motor coordination and balance, forelimb grip strength and spontaneous motor activity of Hdac6 KO mice, and found no difference with control mice (24) . Interestingly, no differences were observed in aggregate load of mutant huntingtin, suggesting that the role of Hdac6 in huntingtin aggregate clearance is minor or compensated by another protein. Although genetic depletion of Hdac6 indeed resulted in highly increased levels of acetylated a-tubulin, this did not modify behavioral phenotypes in HD mice. In contrast, we found that the absence of Hdac6 successfully modified the disease course in the SOD1 G93A mouse. Hdac6 deletion did not affect disease onset, but significantly extended the survival after disease onset with as much as 60%. This increase in survival after disease onset is relevant for translation to human ALS, as treatment in patients is initiated after disease onset only.
As deletion of Hdac6 from the SOD1 G93A mouse significantly slowed the progression of motor neuron degeneration, these results suggest that in this condition the beneficial effects of the absence of this enzyme (e.g. on axonal transport) are greater than its hazardous effects (e.g. on autophagy). This is in contrast to what has been described for models of HD, AD and SBMA (22) (23) (24) . The benefit of Hdac6 activation rather than inhibition may point towards a more important role of impaired autophagy in the pathological mechanism of these disorders. Hdac6 inhibition was also beneficial in a model for motor neuropathy, most probably by increasing axonal transport through increased levels of acetylated a-tubulin (3). It would be interesting to verify whether the axonal transport in SOD1 G93A mice increases upon deletion of Hdac6. Unfortunately, measurement of axonal transport in adult mouse motor neurons in vitro is not feasible, in contrast to what can be done in sensory neurons (3), and techniques for measuring axonal transport in vivo are still being developed (12) .
The absence of the other tubulin deacetylating enzyme, Sirt2, did not induce neuromuscular abnormalities, but did not modify the motor neuron degeneration in the mutant SOD1 mice either. Surprisingly, we found that although Sirt2 is clearly expressed in the nervous system, its contribution to the regulation of a-tubulin acetylation in this tissue is minor. These results were confirmed in the absence of SOD1 G93A in order to exclude a confounding effect of the presence of SOD1
G93A . This is in contrast to what is generally accepted (25, 26) , but in agreement with the in vivo findings of Bobrowska et al. (27) . Obviously, our data do not exclude that Sirt2 has a subtle effect on acetylation in certain cellular compartments that escape detection by western blot on the total tissue lysate, e.g. the oligodendrocyte, in which Sirt2 is highly expressed (28) . But even then, our data show that deletion of Sirt2 from those compartments does not affect motor neuron degeneration in the SOD1 G93A mouse, in spite of the fact that oligodendrocytes have been shown to contribute to neurodegeneration (29) . Furthermore, as Sirt2 has been recently shown to play a pivotal role in programmed necrosis (7), our data indicate that this type of cell death does not contribute to the process of neurodegeneration such as seen in the SOD1 G93A model of ALS. In conclusion, these findings suggest that inhibition of Sirt2 does not provide beneficial effect on ALS in rodents in vivo, in contrast to what has been reported in in vitro and Drosophila models of PD (5) and HD (4, 6) . In contrast, Hdac6 inhibition may be an appealing therapeutic strategy in ALS, as deletion of Hdac6 attenuates motor neuron degeneration in the SOD1 G93A mouse. This attenuation is associated with an increase of acetylated a-tubulin, suggesting that its protective mechanism is related to changes in intracellular transport.
METHODS
Additional information is provided in Supplementary Methods.
Transgenic mice
Sirt2 KO mice, obtained by mating conditional Sirt2 KO mice (16) with CMV-Cre mice, and Hdac6 KO mice (17) were maintained in a C57Bl6/J background. Mice overexpressing human SOD1 G93A [B6SJL-TgN(SOD1-G93A)1Gur; The Jackson Laboratory] were crossed into a C57Bl6 background for more than 20 generations. All animals were housed under standard conditions according to the guidelines of the University of Leuven.
Disease onset and survival
To determine disease onset in SOD1 G93A mice, motor performance was evaluated twice every week by the PaGE test. For this, mice were placed on a wire grid upside down until they drop or reach the maximum of 60 s. Failure on the PaGE test was designated by dropping of the mouse before 60 s. Three SOD1 G93A /Hdac6 Y/+ mice and three SOD1 G93A / Hdac6 Y/2 mice were excluded from this test based upon poor initial performance, i.e. failure within the first 4 weeks of scoring. Survival was determined by loss of the righting reflex within 30 s. When this was the case, the mouse was sacrificed and this time point (equal to end stage) was considered as the time of death. Both the disease onset and survival are presented as Kaplan-Meier curves. For all the experiments, the investigator was blinded for the genotype.
Nerve conduction study
Mice were anesthetized with isoflurane and placed on a heating pad to maintain body temperature. Nerve conduction was measured using sub-dermal needle electrodes (Technomed Europe) and a Medelec EMG monitor (Medelec Vickers/Modul USA). To measure the compound muscle action potential (CMAP), the stimulating electrode was placed at the sciatic notch and the recording electrode at the level of the gastrocnemius muscle.
Histological analyses
Mice were sacrificed using CO 2 immediately followed by dissection of the gastrocnemius muscle, which was instantly frozen in isopentane cooled with liquid nitrogen. To determine NMJ innervation, 40 mm thick longitudinal sections were stained with Alexa 555 conjugated a-bungarotoxin (1/500; Invitrogen) and rabbit anti-NF200 (1/200; Sigma) to visualize the axon innervating the NMJ. More than 100 NMJs spread over three to four sections of the gastrocnemius muscle were scored per animal. After transcardiac perfusion with phosphate buffered saline (PBS) and PBS with 4% paraformaldehyde (PFA), the lumbar region of the spinal cord was dissected, further fixed with 4% PFA, dehydrated in 30% sucrose solution and embedded in OCT medium (VWR). Sixty cryosections of 20 mm thickness each were made. Every sixth cryosection was stained with cresyl violet (Sigma) and used for quantitative analysis of the number of neurons. Thus, in total 10 sections were analyzed per spinal cord covering a range of 1.2 mm. At ×10 magnification, the area of normal appearing neurons with nucleoli in the ventral horn was calculated using AxioVision (version 4.8, Carl Zeiss) and the number of neurons in different size groups was determined.
Statistics
Analyses were performed using SPSS 16.0.2 software. Log-rank was used to analyze survival and disease onset; data from accelerating rotarod were analyzed by repeated measures ANOVA. Univariate ANOVA was applied for neuron counts. Student's t-test or one-way ANOVA was used for analyses of nerve conduction, disease duration, mRNA expression levels and protein expression levels. Chi-square test Pearson uncorrected was used to analyze the frequencies of NMJ denervation. a was a priori set at 0.05. Bonferroni's correction was applied in cases of multiple comparisons.
Study approval
All animal experiments were approved by the local Ethical Committee of the University of Leuven, Belgium (P020/ 2010).
